autoantibodies in autoimmune pancreatitis自身抗体在自身免疫性胰腺炎.pdfVIP

Hindawi Publishing Corporation International Journal of Rheumatology Volume 2012, Article ID 940831, 8 pages doi:10.1155/2012/940831 Review Article Autoantibodies in Autoimmune Pancreatitis Daniel S. Smyk,1 Eirini I. Rigopoulou,2 Andreas L. Koutsoumpas,1 Stephen Kriese,1 Andrew K. Burroughs,3 and Dimitrios P. Bogdanos1, 2, 4 1 Institute of Liver Studies, King’s College London School of Medicine, King’s College Hospital, Denmark Hill, London SE5 9RS, UK 2 Department of Medicine, University of Thessaly Medical School, Viopolis, 41110 Larissa, Greece 3 The Sheila Sherlock Liver Centre and University Department of Surgery, Royal Free Hospital, London NW3 2QG, UK 4 Research Group of Cell Immunotherapy and Molecular Immunodiagnostics, Institute of Biomedical Research Technology, Centre for Research and Technology-Thessaly (CE.RE.TE.TH), 41222 Larissa, Greece Correspondence should be addressed to Dimitrios P. Bogdanos, dimitrios.bogdanos@kcl.ac.uk Received 31 December 2011; Revised 19 April 2012; Accepted 21 April 2012 Academic Editor: Kazuichi Okazaki Copyright © 2012 Daniel S. Smyk et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Autoimmune pancreatitis (AIP) was first used to describe cases of pancreatitis with narrowing of the pancreatic duct, enlargement of the pancreas, hyper-γ-globulinaemia, and antinuclear antibody (ANA) positivity serologically. The main differential diagnosis, is pancreatic cancer, which can be ruled out through radiological, serological, and histological investigations. The targets of ANA in patients with autoimmune pancreatitis do not appear to be similar to those fo